Manufacturing News and Research

RSS

Manufacturing is the production of products across all industries, on a large-scale, using machinery.

Antares Pharma third quarter total revenues increase 26% to $3.9M

Antares Pharma, Inc. today reported financial and operating results for the third quarter ended September 30, 2011.

8 Nov 2011

QRxPharma receives date for US pain drug launch, pending approval

Australian pain-relief drug developer QRxPharma (QRX) has announced today that they have received from the US Food & Drug Adminstration.

8 Nov 2011

Prostate cancer drug market forecast to grow from $3.6 billion in 2010 to $10.1 billion in 2020

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, driven by the launches of several promising emerging therapies, the prostate cancer drug market will experience robust growth over the next decade, increasing from $3.6 billion in 2010 to $10.1 billion in 2020 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

7 Nov 2011

DuoCort Pharma granted marketing authorization for adrenal insufficiency drug, Plenadren in Europe

The Swedish specialty pharma company, DuoCort Pharma, announced today that the European Commission has granted a European Marketing Authorisation for Plenadren (hydrocortisone, modified release tablet), an orphan drug for treatment of adrenal insufficiency in adults, bringing these patients their first pharmaceutical innovation in over 50 years.

7 Nov 2011

Researchers develop new image sensors for 3-D endoscopes

The surgeon carefully guides the endoscope through the patient's nasal cavity to the operation zone. It is a delicate procedure for which the surgeon has to prepare in detail before commencing the actual intervention.

5 Nov 2011

Octapharma receives FDA approval for octagam to treat disorders of immune system

The U.S. Food and Drug Administration (FDA) yesterday cleared the way for the U.S. market return of octagam, the Octapharma USA product used to treat disorders of the immune system.

5 Nov 2011

Opexa reports net loss of $1.30 million for third quarter 2011

Opexa Therapeutics, Inc., a company developing Tovaxin, a novel T-cell therapy for multiple sclerosis (MS), today reported financial results for the quarter ended September 30, 2011 and provided an overview of recent corporate developments.

5 Nov 2011

American Vanguard third quarter net sales increase 8% to $73.8 million

American Vanguard Corporation, today announced financial results for the third quarter and nine month period ended September 30, 2011.

5 Nov 2011

Kenyan company receives WHO prequalification for generic ARV

"The cost of HIV/AIDS medicine is expected to drop by 30 percent in Kenya, enabling more people to access life-prolonging drugs, after the World Health Organization (WHO) gave the green light to a local company manufacturing generics, The Star newspaper reported on Wednesday," AlertNet reports.

4 Nov 2011

Savient third quarter net loss decreases to $27.4 million

Savient Pharmaceuticals, Inc. reported financial results for the three and nine months ended September 30, 2011, which reflect the Company's continuing investment in the U.S. launch of KRYSTEXXA (pegloticase). Savient ended the quarter with $202.7 million in cash and short-term investments, a decrease of $37.6 million for the quarter.

3 Nov 2011

Columbia Laboratories third quarter total net revenues decrease to $4.9 million

Columbia Laboratories, Inc. today reported financial results for the three- and nine-month periods ended September 30, 2011.

3 Nov 2011

Clinical-grade viral vector can cure choroideremia

Researchers at Ohio State University Medical Center and Nationwide Children's Hospital have developed a viral vector designed to deliver a gene into the eyes of people born with an inherited, progressive form of blindness that affects mainly males.

3 Nov 2011

New laser technique could create tissue scaffolds, microneedles

In the emerging field of tissue engineering, scientists encourage cells to grow on carefully designed support scaffolds. The ultimate goal is to create living structures that might one day be used to replace lost or damaged tissue, but the manufacture of appropriately detailed scaffolds presents a significant challenge that has kept most tissue engineering applications confined to the research lab.

3 Nov 2011

Obama takes action to address drug shortages

President Barack Obama issued an executive order Monday directing the Food and Drug Administration to, among other steps, speed up reviews of manufacturers' applications to begin or alter production of a drug in potentially short supply.

2 Nov 2011

SurModics to sell Pharma assets to Evonik for $30 million

SurModics, Inc., a leading provider of surface modification technologies to the healthcare industry, announced today that it has entered into a definitive agreement to sell its SurModics Pharmaceuticals assets to Evonik Industries AG for $30 million in cash.

2 Nov 2011

GSK, Alnylam collaborate to apply VaxiRNA technology for influenza vaccine production

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today it has formed a collaboration with GlaxoSmithKline (GSK) focused on Alnylam's VaxiRNATM technology for certain GSK vaccine products, including influenza. VaxiRNA is a new RNAi technology for the enhanced production of viruses used in the manufacture of vaccine products. GSK, a leading vaccine manufacturer, is the first company to form a collaboration accessing this new platform.

2 Nov 2011

NovaSterilis reports significant findings from sterilization of absorbable suture study

NovaSterilis Inc. a leader in the development and commercialization of supercritical carbon dioxide (SCCO2) technology in collaboration with CC Chu Ph.D (Cornell) reports successful findings from research funded by a National Institutes of Health (NIH) phase l grant. These results meet the study goal to sterilize absorbable sutures to a sterility assurance level 10-6 (SAL6) without chemical or mechanical degradation. NovaSterilis intends to apply for phase II funding to develop the process ready for commercial application.

1 Nov 2011